Swiss Ikerian AG’s US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside a strategic partnership.
https://european-biotechnology.com/wp-content/uploads/2024/10/ikerian.png8001412Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-10-16 15:25:442024-10-16 15:25:44Swiss Ikerian AG partner with Sanoptis Inc to market AI-image analysis